Background: We compared outcomes after breast-conserving therapy (BCT) and mastectomy in multicentric (MC)/multifocal (MF) versus unifocal breast cancer.
Patients presenting with ipsilateral multicentric (MC)/ multifocal (MF) breast cancer pose a challenge to their surgeons and oncologists. MC disease is usually distinguished from MF disease as implying grossly separate tumors in separate quadrants or those separated by >4-5 cm, whereas MF lesions are closer and within the same quadrant [1] . A number of decades ago, Holland et al. published a report that >60% of the patients treated with mastectomies for known unifocal disease were found to have more than one focus. Interestingly, 43% of the tumors were found >2 cm from the reference tumor. Other studies reported MC/MF incidence to range between 6% and 75% [2] [3] [4] [5] [6] [7] [8] [9] .
With the advent of magnetic resonance imaging (MRI) as a screening modality and preoperative procedure, the diagnosis of MF disease is often made preoperatively. A recent meta-analysis based on 19 studies (n = 2610) demonstrated that MRI detected additional 16% breast cancer foci not identified by traditional exams [10] .
MC disease has traditionally been considered an indication for mastectomy, whereas breast-conserving therapy (BCT) in the setting of MF disease has been more controversial and dependent on other factors. Women with two or more primary tumors in separate quadrants of the breast are generally not considered candidates for BCT, whereas patients with multiple gross tumors in the same quadrant must be carefully assessed for suitability because studies in this area are not definitive [1] .
One consequence of the advent of the MRI is an increase in the rate of mastectomies partially related to increased suspicion of MC/MF disease on imaging. As a result, the implication of MC/MF disease for decision making in regard to BCT for patients with breast cancer is of increasing importance.
Our objectives were to: (i) determine to what extent the presence of MC/MF was associated with the use of mastectomy, (ii) determine the factors that were associated with the use of BCT in the presence of MC/MF disease and (iii) determine whether the presence of MC/MF increased the rate of local relapse in patients treated with BCT.
methods
All women diagnosed with stage I-II breast cancer between 1989 and 2005 and referred to the BC Cancer Agency (BCCA) were included. Women were classified as having Unifocal (U) or MC/MF disease. Patients with previous contralateral breast cancer (CBC) or synchronous CBC diagnosed within 6 months were excluded. Patients who had received neoadjuvant treatment were excluded as well. MC/MF disease was defined as two or more invasive lesions anywhere in the same breast based on pathology report. MC/MF, age, histology (ductal/lobular), size of the tumor (£1, 1.1-2, 2.1-5 cm), number of involved axillary lymph nodes (0-3), margin status (positive/ negative), tumor grade, estrogen receptor (ER) status, lymphovascular invasion (LVI), extensive lobular carcinoma in situ, extensive ductal carcinoma in situ (DCIS), type of surgery, number of dissected axillary lymph nodes, adjuvant endocrine therapy, adjuvant chemotherapy and radiation therapy were assessed.
The BCCA has the mandate for cancer control in BC. This includes operation of five regional cancer centers, developing protocol treatment guidelines, provision of 100% of radiation therapy in BC and management of the provincial budget for all antineoplastic drugs. In 2008, the province had a population of 4.4 million and there were 2897 new breast cancers diagnosed. Approximately 80% of patients with a new diagnosis of breast cancer were referred to a BCCA cancer clinic. The referral rate is higher for patients with tumors requiring radiation or systemic therapy than for patients without such indications [11] . The Breast Cancer Outcomes Unit database contains prospectively recorded demographic, pathologic, staging, initial treatment and outcome information for patients diagnosed with breast cancer in BC since 1 January 1989 and who were referred to the BCCA.
In regard to our first objective, to determine whether presence of MC/MF is associated with the use of mastectomy, we compared the use of BCT and mastectomy according to prognostic factors, including presence of MC/MF, extensive DCIS, age, grade, histology, nodal status and tumor size by univariate and multivariate analysis (MVA).
For our second objective, to determine which factors are associated with the use of BCT in those patients with MC/MF disease, we compared the use of BCT and mastectomy within the MC/MF patients specifically according to prognostic factors, including presence of MC/MF, extensive DCIS, age, grade, histology, nodal status and tumor size on univariate and MVA.
To study our final objective, to determine whether the presence of MC/MF disease increased the risk of local relapse in those treated with BCT, we compared relapse rates for those treated with BCT or mastectomy incorporating prognostic factors significant for relapse on univariate analysis including MC/MF. Locoregional relapse and breast cancer-specific survival rates were also calculated and presented for completeness. Because there was an imbalance in prognostic factors between those treated with BCT and mastectomy, we carried out a separate analysis matching cases with unifocal disease 3 to 1 to those with MC/MF disease and compared their outcomes for local relapse. Matched analysis was carried out on the following parameters: T stage (in categories as per Table 1 ), nodal status, LVI, ER, DCIS, histology category (ductal, lobular, others) and margins.
statistical analysis
The balance of risk factors for relapse was compared between MC/MF and U patients in the BCT and mastectomy patients using the chi-square test or Fisher's exact test (for categorical data) and the Wilcoxon rank sum test (for continuous data). The balance of risk factors between patients treated with mastectomy and BCT for those in the MC/MF was also compared using similar tests. Binary logistic regression analyses were carried out to identify risk factors associated with mastectomy.
For both the local and locoregional relapse end points, we calculated the actuarial relapse rates for patients who received BCT using the competing risk method according to MC/MF versus U status. Fine and Gray MVAs were carried out including all variables significant on univariate analysis and MC/MF disease status. For the matched-pair analysis in the BCT cases, all MC/MF case were matched to three U cases on tumor stage, nodal status, LVI, ER status, presence of extensive DCIS, histology (ductal versus lobular) and margin status (positive or negative). Of the 300 MC/MF BCT cases, 289 were successfully matched to three U cases on all variables; for the remaining 11 cases, only one or two U cases were able to be matched on all factors.
This study was approved by the BCCA Research Ethics Board.
results
A total of 19 754 women met the inclusion criteria (94% U, 6% MC/MF). The median follow-up was 7.9 years. With regard to our first objective, whether the presence of MC/MF was associated with the use of mastectomy, we compared the distribution of patient, tumor and treatment characteristics, including the variable for MC/MF or U tumor, by type of surgery in Table 1 . The factors significantly associated with surgery type (BCT versus mastectomy) on univariate analysis were incorporated into an MVA. The following factors were statistically associated with the use of mastectomy on MVA: presence of extensive DCIS [odds ratio (OR) = 0.5, P < 0.001], older age (OR = 0.53 for >70 versus <50, P < 0.001), higher grade (OR = 0.82, P < 0.001 for grade 2-3 versus grade 1), lobular histology (OR = 0.68 versus ductal, P < 0.001), nodal status (OR = 0.63 for 1-3 nodes positive versus none, P < 0.001), tumor size (OR = 0.39 for 2.1-5.0 cm tumors versus £1.0 cm, P < 0.001 and OR = 0.84 for 1.1-2.0 cm tumors versus £1.0 cm, P < 0.001) and presence of MC/MF (OR = 0.2, P < 0.001). (OR < 1 means a patient was more likely to have been treated with mastectomy). Therefore, the presence of MC/MF disease was a factor strongly associated with the use of mastectomy even after accounting for other prognostic factors.
In regard to our second objective, what factors were associated with the use of BCT in the 1187 MC/MF cases, we compared the balance of prognostic factors for the 300 patients that underwent BCT and the 887 patients that underwent mastectomy (Table 2) . In general, patients who had BCT were characterized by better tumor characteristics as compared with the Mastectomy group. Those factors significant on univariate analysis, as shown in Table 2 , were incorporated into a multivariate logistic regression model. The following factors were statistically associated with the use of BCT within the MC/MF patients: absence of DCIS (OR = 1.7, P = 0.001), age 50-69 years (OR = 2.1 versus women <50, P < 0.001) and smaller tumor size (OR = 2.4 for £1.0 cm tumors versus those 2.1-5.0 cm, P < 0.001 and OR = 1.9 for tumors £1.0 cm versus those 1.1-2.0 cm, P < 0.001). (OR > 1 means the factor was associated with the use of BCT.) Therefore, in the presence of MC/MF disease, factors that were associated with the use of BCT were absence of extensive DCIS, small tumor (size £1.0 cm) and age in the range of 50-69 years. In addition, although we were unable to distinguish MC from MF patients, the conservative assumption is that the cases treated with BCT were also MF.
With regard to our third objective, does MC/MF increases the risk of local relapse in those treated with BCT, we first compared the cumulative 10-year local recurrence rates among those with U and MC/MF disease, which were 4.6% [95% Annals of Oncology original articles confidence interval (CI) 4.1% to 5.0%] versus 5.5% (95% CI 2.6% to 9.9%) for the patients who underwent BCT, P = 0.75 ( Figure 1 ). By comparison, for those treated with mastectomy, the cumulative 10-year local recurrence rates among the U and MC/MF disease groups were comparable: 5.8% (95% CI 5.2% to 6.5%) versus 6.5% (95% CI 4.7% to 8.7%), P = 0.74 (Figure 2) .
The Fine and Gray MVA for local relapse in the BCT group was carried out to adjust for any differences in patient and tumor characteristics between the U and MC/MF groups. From Table 3 , it is clear that patients with MC/MF disease treated with BCT tended to be of lower risk than the patients with U disease. The MC/MF group had slightly smaller (35% versus 27% were £1 cm), more ER-positive (80% versus 73%) tumors and more often received systemic therapy (74.3% versus 67.4%) compared with the U group. However, the MC/MF group had more lobular tumors (11.7% versus 6.4%) and more often had extensive DCIS (25.7% versus 12.7%) compared with the U group. Significant characteristics from the univariate analysis were included in the multivariate model: age, number of positive nodes, grade, ER, LVI, extensive DCIS, chemotherapy, hormonal therapy and margin status. The MC/MF disease variable did not reach a statistically significant P value but was added to the MVA since this was the variable of interest. MVA found that the following characteristics increase the risk of local recurrence: lymph node involvement (1-3 positive nodes versus 0) hazard ratio (HR) = 1.58 (95% CI 1.22-2.04), higher grade (grade 2 versus 1) HR = 1.76 (95% CI 1.23-2.53) and (grade 3 versus 1) HR = 2.46 (95% CI 1.66-3.66), extensive DCIS HR = 1.48 (95% CI 1.14-1.92) and positive margins HR = 2.14 (95% CI 1.60-2.87). Favorable parameters were: older age HRs = 0.61 (95% CI 0.47-0.80), 0.58 (95% CI 0.43-0.79) and 0.37 (95% CI 0.25-0.54) for ages 50-59, 60-69 original articles Annals of Oncology and 70+, respectively, (age <50 as baseline group), adjuvant systemic chemotherapy HR = 0.63 (95% CI 0.47-0.86) and adjuvant hormonal therapy HR = 0.44 (95% CI 0.34-0.57). ER positivity was a strong predictor of local relapse (P < 0.001). However, the risk ratio between the ER-positive and -negative cases was not constant and thus, risk difference between these groups has been modeled in a fashion, which allows this risk to change over time. The reduction in risk associated with ER positivity appears to diminish over time. MC/MF disease did not have a statistically significant impact on local recurrence (HR = 1.17, 95% CI 0.62-2.22; P = 0.63). For completeness, we also analyzed locoregional and breast cancer-specific survival outcomes. The 10-year cumulative locoregional relapse risk for the BCT group was 6.1% (95% CI 5.6% to 6.6%) versus 6.7% (95% CI 3.5% to 11.2) in the U and MC/MF groups, respectively, P = 0.95. The impact of MC/MF disease on locoregional relapse was not significant on MVA (HR = 1.17, 95% CI 0.67-2.04; P = 0.58). The 10-year cumulative rate of breast cancer-specific death was 8.2% (95% CI 7.6% to 8.8%) in the unifocal versus 5.5% (95% CI 2.2% to 10.8%) in the MC/MF group. The 10-year cumulative rate of death from any cause was 17.7% (95% CI 16.9% to 18.6%) in the unifocal versus 13.5% (95% CI 8.2% to 20.0%) in the MC/MF group. In the MVA for breast cancer specific survival (BCSS) and overall survival (OS) end points, we did not find the MC/MF characteristic to have significant impact on either of these end points; HR for BCSS = 0.77 (95% CI 0.45-1.34), P = 0.36 and for OS: HR = 0.71 (95% CI 0.47-1.08), P = 0.11.
As the BCT group had a disproportionate number of U cases relative to MC/MF cases (11 000+ versus 300) with different risk factor distributions, a matched-pair analysis was also carried out. A 3 : 1 match (unifocal cases : MC/MF cases) was done on the following factors: T stage (in categories as per Table 1 ), nodal status, LVI, ER, DCIS, histology (ductal/ lobular) and margins as described above. A match could not be found only for 4 of 300 MC/MF cases. The local and locoregional relapse rates were similar across the two groups; the 10-year local recurrence rate for unifocal cases was 4.3% (95% CI 2.8% to 6.1%) and for MC/MF 5.6% (95% CI 2.7% to 10.1%). The HR estimate was: 1.09 (95% CI 0.55-2.16), P = 0.78. For locoregional relapse, the 10-year rates were U 4.8% (95% CI 3.4% to 6.7%) and for MC/MF 6.8% (95% CI 3.6% to 11.5%) HR 1.09 (95% CI 0.55 to 2.16), P = 0.60.
discussion
In our population-based study, we found that local relapse rates were comparable for the unifocal and MC/MF groups, regardless of whether the local therapy was mastectomy or BCT. In addition, the event rate was quite similar among the different groups regardless of type of surgery. In general, the MC/MF incidence in our study was lower than the incidence that is described in some other studies [2, [4] [5] [6] [7] [8] [9] . This can be attributed to the nature of a population-based study. The data were retrieved from the charts as were available for the clinicians with no specific pathology/radiology focus to capture MC/MF disease. In addition, advances in screening and diagnostic imaging overtime may have had an impact on the ability to identify MC/MF breast cancer.
We assume that the unifocal group includes malignant centers/foci that were not identified. Even so, our results are reassuring. Not only that the local recurrence rates among the unifocal and MC/MF groups were equal (when patients had the same type of surgery), but that the local recurrence rates were low. This is especially striking in light of the finding of a higher positivity margin rate for the BCT (10%) versus 4.6% for the Mx group (P = 0.001). The local recurrence event rates are comparable with [12] or lower [13] than those documented in previous smaller studies that reported on MC/MF disease treated with BCT. When the local and regional events were joined and analyzed as one group, again despite the larger event rate, no significant difference in locoregional recurrence rate was shown. The presence of MC/MF is likely a factor that is considered in the final decision making regarding the appropriateness of BCT. Of those patients treated with BCT, only 2.5% were MC/MF compared with 11.4% of those treated with mastectomy. Overall, 63% of unifocal patients in our series had BCT, whereas only 25% of MC/MF patients had BCT. Therefore, it is likely that either the presence of MC/MF was a strong factor in the determination of local therapy or that it is highly correlated with other factors that affect this decision. In an attempt to address this potential bias, we carried out a matched analysis 3 : 1 (unifocal : MC/MF) for the BCT group, which matched patients according to tumor characteristics. We chose matches from the 11 000+ unifocal patients that most resembled the 300 MC/MF patients with respect to tumor characteristics. In this analysis, patients in both groups were balanced on risk factors and received identical local treatment and outcome rates were nearly identical. This provided additional support that MC/MF is not a risk factor for local or locoregional relapse. MC/MF disease has been found to be correlated with other risk factors for relapse, such as positive margins, extensive intraductal and lobular carcinoma component, and with the risk of residual disease on reexcision [14] [15] [16] . However, the current study found that a select group of breast cancer patients with MC/MF disease can be managed with BCT without an increase in the risk of local or locoregional relapse compared with patients with unifiocal disease. When other risk factors for relapse are accounted for, MC/MF disease was not an independent risk factor for relapse. The strongest parameters that predicted local recurrence were higher grade compared with lower grade (HR 2.46) and positive margins (HR 2.14). These parameters together with other important ones such as age, extent of DCIS and number of positive nodes help to estimate the chances for recurrence and might add to the surgical planning decision.
In regard to overall and breast cancer-specific survival, neither the mastectomy nor the BCT group showed inferior outcomes with MC/MF disease. The final MVA did not find MC/MF disease to be an independent factor. These results are consistent with previous smaller and earlier studies [4, 6, 17] .
In contrast to what was found with these data, there are several publications that found MC/MF as a bad prognostic factor with direct impact on survival [17] [18] [19] .
Although, our series is, to our knowledge, the largest population-based series on BCT in MC/MF disease, there are some potential limitations. As the selection of local therapy was multifactorial and nonrandomized, comparison of outcome with mastectomy and BCT is potentially biased by selection of patients for certain type of surgery. Since part of our study population predated the time when human epidermal growth factor receptor 2 (HER2/neu receptor) status was regularly reported, this could add to the imbalance among the groups. However, as previous studies showed that the HER-2-positive group is a relatively small group, we believe that it is unlikely to cause significant imbalance. In addition, we cannot rule out a small impact of MC/MF on outcome that would have been revealed with longer follow-up. As we did find that systemic therapy was associated with a decreased risk of relapse in those MC/MF patients treated with BCT, the appropriate use of systemic therapy may be important in achieving low recurrence rates.
Our analysis is also limited by our inability to separate MC and MF cases, and therefore, one must make conservative assumptions and assume that most of the BCT cases were MF when type of surgery is considered. Similarly, one has to be cautious in generalizing the definition of MC/MF, as the outcomes and selection of cases for BCT may depend in part on how MF and MC are defined. For example, the implications of MF disease defined by histological description by the pathologist may be different from a definition confined to only grossly identified separate lesions on exam, imaging or gross pathologic exam. Again, a conservative assumption is that our findings with respect to the safety of BCT apply to patients with pathologically, as opposed to clinically identified, MF. The MVA also suggests that our results may be most applicable to those women aged 50-69 years with smaller tumors without associated DCIS.
Our study suggests that the presence of MC/MF disease is a factor considered in selection of BCT, that those MC/MF cases treated with BCT have the aforementioned low-risk features and that the use of BCT in such cases is a reasonable option. references
